RxDoctor Payments Data

Michelle Woodard, MD

Internal Medicine · Watkinsville, GANPI 1912988288

Payments from drug & device makers

$3,522in general payments, 2019–2025

Across 209 payments — averaging $16.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$572
  • Amgen$371
  • Pfizer$346
  • Astellas Pharma US Inc$343
  • Takeda Pharmaceuticals U.S.A., Inc.$311
  • Boehringer Ingelheim$212
  • plus $1K from 27 others

What the payments were for

  • Food & beverage$3,43598%
  • Education$872%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,522 in reported general payments places this provider in the 80th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$127,533
Medicare patients
230
Services billed
2,535

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide126$157,897
Repatha SureclickEvolocumab121$76,898
JardianceEmpagliflozin75$72,013
TrulicityDulaglutide44$54,881
EliquisApixaban54$54,271
XareltoRivaroxaban46$45,229
MyrbetriqMirabegron61$36,186
OzempicSemaglutide28$34,565
JanuviaSitagliptin Phosphate18$24,375
BelsomraSuvorexant31$15,469
LinzessLinaclotide12$14,897
TrintellixVortioxetine Hydrobromide26$14,881
Praluent PenAlirocumab30$14,589
ArexvyRsvpref3 Antigen/As01e/Pf43$13,226
GemtesaVibegron18$12,721

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$572$212,778170 claims
Boehringer IngelheimJardiance$212$72,01375 claims
PfizerEliquis, Paxlovid$346$59,74596 claims
Johnson & JohnsonXarelto$72$45,22946 claims
MerckJanuvia, Belsomra$123$39,84449 claims
Astellas Pharma US IncMyrbetriq$343$36,18661 claims
Novo NordiskOzempic$37$34,56528 claims
GSKArexvy, Shingrix$36$21,60081 claims
AbbVieLinzess, Synthroid, Armour Thyroid$64$21,25667 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$311$14,88126 claims
Sumitomo Pharma America, Inc.Gemtesa$72$12,72118 claims
AstraZenecaFarxiga$79$12,70216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Watkinsville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →